SCHEMBL1421155

SCHEMBL1421155

N#Cc1ccc2cc(-c3ccc(-n4ccnc4)nc3)[nH]c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 5/20 0.46
CYP1A2 P05177 3/20 0.46
CYP3A4 P08684 3/20 0.46
ALOX15 P16050 3/20 0.46
CYP2C19 P33261 3/20 0.46
HSD17B10 Q99714 3/20 0.46
CDK5 Q00535 3/20 0.46
CDK5R1 Q15078 3/20 0.46
CYP2D6 P10635 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
TDP1 Q9NUW8 1/20 0.43
ITK Q08881 1/20 0.39
PIM1 P11309 1/20 0.38
ADORA3 P0DMS8 2/20 0.38
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
RET P07949 1/20 0.37
CD38 P28907 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483693 0.91 CYP19A1 (0.58) CYP19A1CYP1A2CYP3A4ALOX15CYP2C19
SCHEMBL1484074 0.85 GAA (0.42) CYP19A1CYP1A2CYP3A4ALOX15CYP2C19
SCHEMBL1422658 0.83 PIM1 (0.40) CYP19A1CYP1A2CYP3A4CYP2C19HSD17B10
SCHEMBL13577817 0.83 PIM1 (0.40) CYP19A1CYP1A2CYP3A4ALOX15CYP2C19
SCHEMBL1425629 0.80 CDK5 (0.46) CYP19A1CDK5CDK5R1ITKPIM1
SCHEMBL1484008 0.80 CYP11B1 (0.48) CYP19A1CYP1A2CYP3A4CYP2C19HSD17B10
SCHEMBL1483709 0.79 GAA (0.42) CYP19A1CYP1A2CYP3A4ALOX15CYP2C19
SCHEMBL1422916 0.77 CYP1A1 (0.45) CYP19A1CYP1A2CYP3A4CYP2C19HSD17B10
SCHEMBL1484209 0.76 CYP19A1 (0.46) CYP19A1CYP1A2CYP3A4HSD17B10CDK5
SCHEMBL13577804 0.76 PIM1 (0.40) CYP19A1CYP1A2CYP3A4ALOX15CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US claimed
EP-2296474-A1 NOVEL SUBSTITUTED INDOLES Merck Sharp & Dohme Corp. (US) 2011-03-23 EP claimed
WO-2009155024-A1 NOVEL SUBSTITUTED INDOLES MERCK & CO., INC. (US) 2009-12-23 WO claimed
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US disclosed
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US disclosed
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110076230-A1 Novel Substituted Indoles APP, BACE1, PSEN1 CYP19A1 3222/4885CYP1A2 1001/4885CYP3A4 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.